Chlamydia Trachomatis Infections: Epidemiology and Treatment Strategies

Chlamydia trachomatis remains the most prevalent bacterial sexually transmitted pathogen globally, with tens of millions of new infections each year. Infection is frequently asymptomatic, particularly at extra-genital sites, yet carries risks of pelvic inflammatory disease, infertility, adverse pregnancy outcomes and enhanced susceptibility to HIV. Surveillance data highlight high incidence among adolescents and young adults, with hidden reservoirs in anorectal and pharyngeal mucosa that escape symptom-based screening. Molecular diagnostics based on nucleic acid amplification tests have transformed detection but cannot differentiate viable from non-viable organisms. Standard treatment comprises single-dose azithromycin or a week of doxycycline; however, emerging evidence suggests variable efficacy at anorectal sites and the potential for persistent gastrointestinal colonisation. Reinfection dynamics are influenced by autoinoculation and partner transmission, underscoring the importance of timely partner notification and repeat testing. Current control strategies integrate expanded screening protocols, optimised antimicrobial regimens and behavioural interventions. Addressing gaps in pharmacokinetic data, treatment adherence and viability assessment will be crucial to refine guidelines and reduce the global burden of chlamydial disease.

Research from Nature Portfolio

Recent studies have employed droplet digital PCR combined with viability-PCR to quantify live C. trachomatis in endocervical and rectal specimens with high precision. This approach demonstrated over 90% concordance with conventional platforms in endocervical samples and revealed that nearly 70% of rectal detections represent viable bacteria, even in women abstaining from receptive anal intercourse. These findings support the existence of a gastrointestinal reservoir capable of maintaining infection independently of genital transmission and challenge the adequacy of single-dose azithromycin regimens in achieving complete clearance at extra-genital sites. The work advocates for incorporation of viability assessment in diagnostic algorithms and reconsideration of treatment protocols that address both genital and gastrointestinal niches.

Chlamydia Trachomatis Infections: Epidemiology and Treatment Strategies publication trend

The graph below shows the total number of articles in chlamydia trachomatis infections: epidemiology and treatment strategies across all publications each year (not limited to Nature Index journals).

Technical terms

Nucleic acid amplification test (NAAT): Laboratory assay that amplifies target DNA or RNA to detect the presence of C. trachomatis with high sensitivity.

Droplet digital PCR (ddPCR): Quantitative molecular technique partitioning samples into thousands of droplets for absolute enumeration of nucleic acid targets.

Persistence: Reversible, non-replicative state in the chlamydial developmental cycle enabling temporary evasion of antibiotic killing.

Autoinoculation: Self-transfer of organisms between anatomical sites, for example from the gastrointestinal tract to the genital tract, sustaining infection reservoirs.

References

1. Patterns of within-host spread of Chlamydia trachomatis between vagina, endocervix and rectum revealed by comparative genomic analysis. Frontiers in Microbiology (2023).
2. Highly viable gastrointestinal Chlamydia trachomatis in women abstaining from receptive anal intercourse. Scientific Reports (2025).
3. Viability-PCR Shows That NAAT Detects a High Proportion of DNA from Non-Viable Chlamydia trachomatis. PLOS ONE (2016).
4. What is needed to guide testing for anorectal and pharyngeal Chlamydia trachomatis and Neisseria gonorrhoeae in women and men? Evidence and opinion. BMC Infectious Diseases (2015).
5. Chlamydia trachomatis Incidence and Re-Infection among Young Women – Behavioural and Microbiological Characteristics. PLOS ONE (2012).
6. Treatment challenges for urogenital and anorectal Chlamydia trachomatis. BMC Infectious Diseases (2015).
7. Pharmacokinetics of a single 1g dose of azithromycin in rectal tissue in men. PLOS ONE (2017).
8. Is it time to switch to doxycycline from azithromycin for treating genital chlamydial infections in women? Modelling the impact of autoinoculation from the gastrointestinal tract to the genital tract. BMC Infectious Diseases (2015).
9. Retesting and repeat positivity following diagnosis of Chlamydia trachomatis and Neisseria gonorrhoea in New Zealand: a retrospective cohort study. BMC Infectious Diseases (2017).
10. Detection of Anorectal and Cervicovaginal Chlamydia Trachomatis Infections following Azithromycin Treatment: Prospective Cohort Study with Multiple Time-Sequential Measures of rRNA, DNA, Quantitative Load and Symptoms. PLOS ONE (2013).